Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

In a prospective trial of 75 Chinese patients with histologically proven inoperable hepatocellular carcinoma (HCC), 25 patients were randomised to receive doxorubicin 60-75 mg m-2 intravenously once every 3 weeks, 25 to receive recombinant alpha 2 interferon (rIFN) (Roferon) 9-18 x 10(6) IU m-2 intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, C. L., Wu, P. C., Lok, A. S., Lin, H. J., Ngan, H., Lau, J. Y., Chung, H. T., Ng, M. M., Yeoh, E. K., Arnold, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247256/
https://www.ncbi.nlm.nih.gov/pubmed/2557881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247256/
https://www.ncbi.nlm.nih.gov/pubmed/2557881

Ejemplares similares